Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer OR
• •Histologically confirmed ovarian low malignant potential tumor with invasive recurrence
• •Relapsed after and/or refractory to platinum- and taxane-based chemotherapy
• •Patients in first relapse after a disease-free interval of more than 1 year are eligible
• •Measurable disease outside prior radiation field
• •Availability of a sentinel lesion that is adequate for core biopsy through percutaneous biopsy or simple laparoscopic means
• •Patients with clinical evidence of CNS involvement (abnormal clinical examination) must have a negative CT scan with contrast or MRI of the brain
• •No large volume ascites or pleural effusion
• •PATIENT CHARACTERISTICS:
• •Age:
• •Not specified
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count greater than 1,500/mm\^3
• •Hemoglobin at least 9.0 g/dL (independent of epoetin alfa or transfusion)
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL
• •Transaminases no greater than 2.5 times upper limit of normal
• •Renal:
• •Creatinine no greater than 1.5 mg/dL
• •Cardiovascular:
• •No myocardial infarction or unstable dysrhythmia within the past 6 months
• •No congestive heart failure (CHF), including CHF that may be compensated with furosemide
• •Other:
• •No other invasive malignancy within the past 5 years except noninvasive nonmelanoma skin cancer
• •No active infection
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective barrier contraception during and for 3 months after study completion
• •Concurrent residual, stable, grade 2 or lower peripheral neuropathy allowed at the discretion of the principal investigator (PI)
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior signal transduction therapy
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or carboplatin)
• •Endocrine therapy:
• •At least 4 weeks since prior hormonal therapy
• •Radiotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •See Disease Characteristics
• •Other:
• •Recovered from prior anticancer therapy
• •At least 1 week since prior antibiotics
• •No more than 4 prior anticancer regimens
• •No concurrent ketoconazole, itraconazole, erythromycin, or clarithromycin
• •No concurrent therapeutic warfarin
• •* Patients who can be safely converted over to low molecular weight heparin are eligible
• •No concurrent grapefruit or grapefruit juice
• •No concurrent combination antiretroviral therapy for HIV-positive patients
• •No concurrent alternative or complementary therapies or over-the-counter agents unless approved by the PI
• •Concurrent medications that may alter the metabolism of imatinib mesylate and lead to potential toxicity are allowed at the discretion of the PI